About D’OXYVA®

INTRODUCING D'OXYVA®

About D'OXYVA®.

When used regularly on a daily and weekly basis, D’OXYVA (deoxyhemoglobin vasodilator) has shown to significantly improve microcirculation and promote vessel regrowth (angiogenesis), endothelial function, nutrient production and delivery, partial pressure of oxygen and organ function all the way to cells and vasomotor activity. All these processes in unison promote long-term homeostasis and tissue regeneration.

Pivotal human clinical studies with D’OXYVA have shown extraordinary results for the role of transdermal noninvasive wound care using ultra-purified, nontoxic, FDA-cleared molecules, such as CO2, especially when all other approaches failed.

In an ongoing multiyear, multi-country, multi-center, randomized clinical trial on patients with diabetic foot ulcers, D’OXYVA has demonstrated speeding up diabetic wound healing and ultimately wound closure to an average of 5 weeks.*

In addition, D’OXYVA eliminated pain and improved quality of life factors such as sleep, appetite, and mood in just a week in 100% of subjects. No adverse events of any kind were reported during, and years after, the studies.

Patients and physicians report quicker, more comfortable diabetic wound treatment, wound closure, and overall recovery from trauma and so-called non-healing chronic wounds related to diabetes and cardiovascular complications. Reports of significantly lower instances of pain and infection are nearly universal.

Main Features

    • PAIN-FREE, NONINVASIVE, NONELECTRICAL, TAKES 5 MINUTES
    • AFFORDABLE, CONVENIENT, MAJOR CLINICAL OUTCOMES IN 2-6 WEEKS**
    • PATIENT- & DOCTOR-FRIENDLY; USE AT HOME, IN PRACTICE, OR ON THE GO
    • NON-TOXIC, NON-OPIOID, NO MAJOR ADVERSE EVENT REPORTS, NO OVERDOSE
    • HANDHELD, PORTABLE, NEEDS NO SPECIAL STORAGE
    • EFFECTIVE STANDALONE & ADJUNCT SOLUTION
    • NO ADVERSE INTERFERENCE WITH OTHER MODALITIES
D'OXYVA Advanced Chronic Wound Care

MEASURE / FEEL / SEE RESULTS IN
5 WEEKS**

*Eight years of excellent user feedback and over two dozen clinical studies demonstrated outsized results at clinics and at home with zero major adverse events. For example, significant results have also been recorded for D’OXYVA® (deoxyhemoglobin vasodilator) as a varicose vein treatment while delivering major clinical outcomes for well over 90% of users. Average results are rounded for display, based on number of enrolled subjects in each clinical study with D’OXYVA and user feedback.

Read D’OXYVA Clinical Evidence

**Individual results may vary. Ask your doctor before taking D’OXYVA. For prescription for medical use.

Read D’OXYVA Regulatory Statements

***We will refund your entire D’OXYVA purchase price if you do not experience any measurable improvements (proof of purchase required, improvements of blood flow [perfusion index] measured from absolute baseline without taking D’OXYVA).

Read Circularity’s Return Policy

Latest Breakthroughs

The Blog.

Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA® for Rapid, Economical and Noninvasive Home Treatment of Diabetic Foot Ulcers (DFU)

PASADENA, Calif., Feb. 1, 2021 5:31 AM PST (MORNINGSTAR) Addressing urgent and increased DFU problem related to pandemic lockdowns. Circularity Healthcare announced it had successfully executed a contract with the

Switch To D'OXYVA®.

The only gentle, rapid, and painless transdermal solution without breaking the layers of the skin.

D’OXYVA® (deoxyhemoglobin vasodilator) biotechnology provides an inexpensive, simple and effective method of mild to severe chronic wound care. Its fully noninvasive transdermal approach delivers a host of benefits including but not limited to significant blood flow in the microcirculation (perfusion index), oxygen saturation (SpO2), nutrients, nerve stimulation (parasympathetic), which together are crucial for the complete and painless wound healing process.

Get in touch to avail D’OXYVA® for rapid chronic wound treatment.